Acrivon Therapeutics
ACRV
ACRV
39 hedge funds and large institutions have $191M invested in Acrivon Therapeutics in 2023 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 3 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
2.22% less ownership
Funds ownership: 71.64% → 69.42% (-2.2%)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Holders
39
Holding in Top 10
1
Calls
–
Puts
–
Top Buyers
| 1 | +$6.02M | |
| 2 | +$5.19M | |
| 3 | +$2.23M | |
| 4 |
State Street
Boston,
Massachusetts
|
+$1.08M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$885K |
Top Sellers
| 1 | -$7.94M | |
| 2 | -$2.66M | |
| 3 | -$545K | |
| 4 |
Goldman Sachs
New York
|
-$318K |
| 5 |
Two Sigma Investments
New York
|
-$248K |